Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So nice to wake up here this morning (Wed) to see OGI up 27% in pre market...
well done, John, on increasing your holding here.
I have built up a sizeable stake here over 40k shares... imho: CURLF is a big winner.
Hey, thanks, I will check out that board.
a lot of red around today ... but CURAF is green again ... I like holding and hanging about here...
Shares of Aphria Inc. surged 6.1% toward a 3 1/2-month high in premarket trading Tuesday, after the Canada-based cannabis company reported fiscal second-quarter losses that were in line with expectations and provided an upbeat full-year sales outlook. For the quarter to Nov. 30, Aphria swung to a net loss of C$8.2 million ($6.3 million), or 3 cents a share, from a profit of C$54.8 million, or 22 cents a share, in the same period a year ago. The FactSet consensus was for a per-share loss of 3 cents. Net revenue rose more than 5-fold to C$120.6 million ($92.2 million) from C$21.7 million, but was below the FactSet consensus of C$129.8 million. Kilograms sold rose 18% to 7,062 while cash cost to produce dried cannabis fell 22% to C$1.11 per gram. For fiscal 2020, the company expects revenue of C$575 million to C$625 million, above the FactSet consensus of C$571 million.
https://finance.yahoo.com/m/fb639376-8190-35cf-b5f7-3ae673b679c6/aphria%26%2339%3Bs-stock-surges.html?.tsrc=rss
Pre-market now at + 3.67%
looking good, Las3r.
happy to be holding Aphria
Aphria Inc. Announces Third Consecutive Quarter of Positive Adjusted EBITDA and a 46% Increase in Adult-Use Cannabis Revenue From Prior Quarter
https://finance.yahoo.com/news/aphria-inc-announces-third-consecutive-110000189.html?.tsrc=rss
cheers, brother, yep the best has yet to come... patience pays... and balls break bull***t... Aphria look good into a bright future... hoping tomorrow's figures are another dream come true... good night, it's tomorrow morning where I live...
still holding some sub 2s from '15...
Brilliant post, Mx1001. Thank you, man.
The real money is in medicines....
but we have to have patience ...
the longer-view stoic investor wins...
anyone with patient, and balls, will win with Aphria...
Just look today at GW Pharma...
Sales Keep Growing for GW Pharma’s Cannabis-Based Epilepsy Treatment
Canna medicines will be huge ...
in a short few years investors will look back and say: 'my oh my weren't canna shares so cheap at the start of the decade."
GW Pharma news is great news for the sector, as you state Stocker1.
I piled in there a month or so back....
basically they have two cannabis drugs / medicines on offer, and they have more in the pipeline, and GW will become a mega medicine company.
This is also what I envision for Canopy, more to be gained on the medical side than recreation in the longer term...
mind you we haven't heard much about Canopy's sleeping aid since Bruce walked the plank...
Anyone know what is happening sleep pill wise, or medicines wise, with Canopy...?
Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales
Based on preliminary unaudited financial information, the company expects total net product sales to be approximately $108 million for the fourth quarter and approximately $309 million for the year ended December 31, 2019. Total net product sales of Epidiolex are expected to be approximately $104 million for the fourth quarter and approximately $296 million for the full year. Cash and cash equivalents at December 31, 2019 were approximately $536 million. Fourth quarter and full-year 2019 financial results are expected to be reported on February 25th, 2020.
https://finance.yahoo.com/news/gw-pharmaceuticals-pre-announces-preliminary-230010269.html?.tsrc=rss
New York Will Legalize Marijuana in 2020, Cuomo Vows
Legalizing the drug would pour hundreds of millions into the coffers of a state facing a $6 billion budget gap, he said.
ALBANY, N.Y. — Gov. Andrew M. Cuomo vowed on Wednesday to legalize marijuana in New York, prioritizing a push that fell apart last year amid tensions over who should be allowed to sell the drug and where the revenue should go.
https://www.nytimes.com/2020/01/08/nyregion/state-of-the-state-cuomo-ny.html
A souring bet on cannabis by the American distributor of Corona and Modelo beers has again burnt its profits.
Constellation Brands yesterday wrote down its 38 per cent stake in Canopy Growth, Canada’s largest marijuana grower, by $534 million, knocking its third-quarter profit.
https://www.thetimes.co.uk/edition/business/high-hopes-suffer-new-blow-at-constellation-brands-5933rjsq5
A multiple sclerosis patient who was facing jail for growing cannabis to ease her pain was acquitted today after the case against her collapsed.
Lesley Gibson, 55, and her husband, Mark, received not guilty verdicts at Carlisle Crown Court after being charged for possession and cultivation of the class B drug.
Their home was raided in January last year with police confiscating ten baby cannabis plants and three home-made cannabis chocolate bars. If convicted the pair faced up to five years in prison or an unlimited fine or both.
Medical cannabis has been legal in Britain for more than a year but only under strict conditions. The difficulty of obtaining an NHS prescription means tens of thousands of patients are still using the black market to get the drug.
The MS Society estimates that 10,000 MS patients use cannabis to alleviate muscle spasticity and pain but campaigners say only a handful have so far been prescribed the drug legally.
Two months ago, the National Institute for Health and Care Excellence (Nice) approved a cannabis-based treatment for MS called Sativex but the NHS will only offer it to those with “moderate to severe” spasticity which has not improved while taking other treatments. https://www.thetimes.co.uk/edition/news/ms-patient-who-grew-cannabis-to-ease-her-pain-is-acquitted-on-drug-charges-jr65qrhmg
these canna opponents, or resisters, are like king Canute's courtiers boasting he was so great he could command the tide to go back....
they too will be washed away in the global wave about to drown silly wasteful prohibition ...
wow, fabulous information, thank you very much Mx1001.
thanks for that post, Funman.
Canopy Growth won’t be part of the pot sector carnage, this investor says
https://www.cantechletter.com/2020/01/canopy-growth-wont-be-part-of-the-pot-sector-carnage-this-investor-says/
lol... love your last line...
agree
The legal market for cannabis was worth nearly $11bn globally in 2018, and is expected to reach at least $50bn by 2029, according to Jefferies equity research. Other research groups predict the market could be at least three times that size.
......... Som Seif, chief executive of Purpose, added: “The cannabis sector is still in the infancy stages of a multiyear growth phase and there is ample opportunity for innovation and new discoveries.”
https://www.ft.com/content/16f96759-2850-4202-9b58-da0c6459f679?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content
"The legal market for cannabis was worth nearly $11bn globally in 2018, and is expected to reach at least $50bn by 2029, according to Jefferies equity research. Other research groups predict the market could be at least three times that size.
..... "Several large Canadian companies have been attracted to the UK’s fast-expanding legal marijuana market, including Canopy, the world’s largest publicly traded producer. Last year it bought a stake in UK skincare brand This Works for £43m and has also entered into a partnership with British research group the Beckley Foundation to develop medical cannabis."
https://www.ft.com/content/16f96759-2850-4202-9b58-da0c6459f679?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content
We are still in early days...
Canna sector is so young ....
but growing globally....
have a look at Europe opening up.
"European savers will soon be offered their first opportunity to invest in an exchange traded fund focused on the fast-growing legal marijuana industry. Canadian fund group Purpose Investments plans to launch the Medical Cannabis and Wellness ETF from January 13, which will be Europe’s first such product. The fund will be listed in Germany and made available to investors in the UK, Italy and Ireland."
https://www.ft.com/content/16f96759-2850-4202-9b58-da0c6459f679?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content
This sector is so young .... but growing globally.... look at this.
European savers will soon be offered their first opportunity to invest in an exchange traded fund focused on the fast-growing legal marijuana industry. Canadian fund group Purpose Investments plans to launch the Medical Cannabis and Wellness ETF from January 13, which will be Europe’s first such product. The fund will be listed in Germany and made available to investors in the UK, Italy and Ireland.
https://www.ft.com/content/16f96759-2850-4202-9b58-da0c6459f679?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content
European savers will soon be offered their first opportunity to invest in an exchange traded fund focused on the fast-growing legal marijuana industry. Canadian fund group Purpose Investments plans to launch the Medical Cannabis and Wellness ETF from January 13, which will be Europe’s first such product. The fund will be listed in Germany and made available to investors in the UK, Italy and Ireland.
https://www.ft.com/content/16f96759-2850-4202-9b58-da0c6459f679?desktop=true&segmentId=d8d3e364-5197-20eb-17cf-2437841d178a#myft:notification:instant-email:content
looking like that, Spartan.... now up 2.45% in pm
Financial Times share price forecasts (02-Jan-2020)
(in $CAD)
The 13 analysts offering 12 month price targets for Cronos Group Inc have a median target of 12.00, with a high estimate of 17.00 and a low estimate of 8.00. The median estimate represents a 20.36% increase from the last price of 9.97.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=CRON:TOR
Financial Times share price forecasts (02-Jan-2020)
(in $CAD)
The 8 analysts offering 12 month price targets for Supreme Cannabis Company Inc have a median target of 1.25, with a high estimate of 1.75 and a low estimate of 0.70. The median estimate represents a 98.41% increase from the last price of 0.63.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=FIRE:TOR
Financial Times share price forecasts (02-Jan-2020)
(In $CAD)
The 14 analysts offering 12 month price targets for OrganiGram Holdings Inc have a median target of 7.00, with a high estimate of 13.30 and a low estimate of 4.00. The median estimate represents a 119.44% increase from the last price of 3.19.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=OGI:TOR
Financial Times share price forecasts (02-Jan-2020)
(In $CAD)
The 3 analysts offering 12 month price targets for Khiron Life Sciences Corp have a median target of 4.00, with a high estimate of 4.00 and a low estimate of 3.25. The median estimate represents a 277.36% increase from the last price of 1.06.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=KHRN:CVE
Financial Times share price forecasts (02-Jan-2020)
The 15 analysts offering 12 month price targets for GW Pharmaceuticals PLC- ADR have a median target of 200.00, with a high estimate of 260.00 and a low estimate of 160.00. The median estimate represents a 91.28% increase from the last price of 104.56.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=GWPH:NMQ
Financial Times share price forecasts (02-Jan-2020)
(In $CAD)
The 4 analysts offering 12 month price targets for Curaleaf Holdings Inc have a median target of 10.75, with a high estimate of 13.00 and a low estimate of 7.25. The median estimate represents a 31.42% increase from the last price of 8.18.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=CURLF:QXE
Financial Times share price forecasts (02-Jan-2020)
(In $CAD)
The 21 analysts offering 12 month price targets for Canopy Growth Corp have a median target of 27.00, with a high estimate of 60.00 and a low estimate of 22.00. The median estimate represents a -1.14% decrease from the last price of 27.31.
Financial Times share price forecasts (02-Jan-2020)
(In $CAD)
The 18 analysts offering 12 month price targets for Aurora Cannabis Inc have a median target of 5.00, with a high estimate of 10.53 and a low estimate of 0.00. The median estimate represents a 79.21% increase from the last price of 2.79.
https://markets.ft.com/data/equities/tearsheet/forecasts?s=ACB:TOR
Financial Times share price forecasts (02-01-2020)
(In $CAD)
The 13 analysts offering 12 month price targets for Aphria Inc have a median target of 10.40, with a high estimate of 26.00 and a low estimate of 6.50. The median estimate represents a 53.39% increase from the last price of 6.78.
hopes everyone here gains a happy new year here... still hanging long here... hopefully this is the year Supreme turns supreme...
great good luck to you, Mx10001.... and all Auroraians.....
lol....
something to do with oil.... lol...
happy new year...
just finishing off a curer for the new year hangover....
cannacheers to you, Funman, and all Aphrians...
Why Aurora Cannabis, Canopy Growth, and Other Top Canadian Marijuana Stocks Soared Today
As a dismal 2019 comes to an end, investors appear to be looking to a brighter 2020.
https://www.fool.com/investing/2019/12/31/why-aurora-cannabis-canopy-growth-and-other-top-ca.aspx